Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-07-05
2005-07-05
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S006120
Reexamination Certificate
active
06914049
ABSTRACT:
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.
REFERENCES:
patent: 5187151 (1993-02-01), Clark et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5643867 (1997-07-01), Maack et al.
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5723441 (1998-03-01), Higley et al.
patent: 5840673 (1998-11-01), Buckbinder et al.
patent: 5861273 (1999-01-01), Olson et al.
patent: 5914254 (1999-06-01), Mascarenhas et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 6015786 (2000-01-01), Mascarenhas et al.
patent: 6417330 (2002-07-01), Mascarenhas et al.
patent: 6428781 (2002-08-01), Sakano et al.
patent: 2002/0165155 (2002-11-01), Schaffer et al.
patent: 2003/0035788 (2003-02-01), Mascarenhas
patent: 2003/0092631 (2003-05-01), Deshayes et al.
patent: 0 128 733 (1984-12-01), None
patent: 0 597 033 (1993-02-01), None
patent: WO 95/03817 (1995-02-01), None
patent: WO 95/13823 (1995-05-01), None
patent: WO 96/02565 (1996-02-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 01/87238 (2001-11-01), None
patent: WO 02/24216 (2002-03-01), None
patent: WO 02/34916 (2002-05-01), None
Adams, S. et al. (1995). “Pharmacokinetics and Bioavailability of rhIGF-I/IGFBP-3 in the Rat and Monkey,”Prog. Growth Factor Res.6(2-4):347-356.
Altschul, S.F. et al. (1990). “Basic Local Alignment Search Tool,”J. Mol. Biol.215:403-410.
Asin, J. et al. (2000). “Iron (II) Induces Changes in the Conformation of Mammalian Mitochondrial DNA Resulting in a Reduction of its Transcriptional Rate,”FEBS Letters480:161-164.
Ausubel, F. et al. eds. (1987).Current Protocols in Molecular BiologyGreene Publishing Associates and Wiley-Interscience: New York. (Table of Contents Only.)
Bartfay, W.J. et al. (1999). “A Biochemical, Histochemical, and Electron Microscopic Study on the Effects of Iron-Loading on the Hearts of Mice,”Cardiovascular Pathology8(6):305-314.
Baxter, R.C. (1988). “Characterization of the Acid-Labile Subunit of the Growth Hormone-Dependent Insulin-Like Growth Factor Binding Protein Complex,”J. Clin. Endocrinol. Metab.67(2):265-272.
Baxter, R.C. et al. (1986). “Growth Hormone-Dependent Insulin-Like Growth Factor (IGF) Binding Protein from Human Plasma Differs from Other Human IGF Binding Proteins,”Biochem. Biophys. Res. Comm.139(3):1256-1261.
Baxter, R.C. et al. (1989). “High Molecular Weight Insulin-Like Growth Factor Binding Protein Complex,”J. Biol. Chem264(20):11843-11848.
Bayes-Genis, A. et al. (2001). “Insulin-Like Growth Factor Binding Protein-4 Protease Produced by Smooth Muscle Cells Increases in the Coronary Artery After Angioplasty,”Arterioscler. Thromb. Vasc. Biol.21:335-341.
Blum, W.F. and Ranke, M.B. (1991). “Plasma IGFBP-3 Levels as Clinical Indicators”In Modern Concepts of Insulin-Like Growth FactorsSpencer, E.M. ed., Elsevier: New York. pp. 381-393.
Boles, B.K. et al. (2000). “Phorbol Ester-Induced U-937 Differentiation: Effects on Integrin α3Gene Transcription,”Am. J. Physiol. Lung Cell Mol. Physiol.278:L703-L712.
Butler, A.A. et al. (1998). “Stimulation of Tumor Growth by Recombinant Human Insulin-Like Growth Factor-I (IGF-I) Is Dependent on the Dose and the Level of IGF-I Receptor Expression,”Cancer Res.58:3021-3027.
Byun, D. et al. (2001). “Pregnancy-Associated Plasma Protein-A Accounts for the Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Proteolytic Activity in Human Pregnancy Serum and Enhances the Mitogenic Activity of IGF by Degrading IGFBP-4 in Vitro,”J. Clin. Endocrinol. Metabl.86(2):847-854.
Campbell, P.G. et al. (1998). “Plasminogen Binds the Heparin-Binding Domain of Insulin-Like Growth Factor-Binding Protein-3,”Am. J. Physiol.275(2pt. 1):E321-E331.
Campbell, P.G. et al. (1999). “Insulin-Like Growth Factor-Binding Protein-3 Binds Fibrinogen and Fibrin,”J. Biol. Chem.274(42):30215-30221.
Collett-Solberg, P.F. et al. (1998). “Identification of Novel High Molecular Weight Insulin-Like Growth Factor-Binding Protein-3 Association Proteins in Human Serum,”J. Clin. Endocrinol. Metab.83(8):2843-2848.
Conover, C.A. et al. (2001). “Pregnancy-Associated Plasma Protein-A is the Insulin-Like Growth Factor Binding Protein-4 Protease Secreted by Human Ovarian Granulosa Cells and Is a Marker of Dominant Follicle Selection and the Corpus Luteum,”Endocrinology142(5):2155-2158.
Coppack, S.W. (2001). “Pro-Inflammatory Cytokines and Adipose Tissue,”Proc. Nutr. Soc.60:349-356.
Crofford, L.J. (May, 2002). “Specific Cyclooxygenase-2 Inhibitors: What Have We Learned Since They Came Into Widespread Clinical Use?”Curr. Opin. Rheumatol.13:225-230.
Degertekin, M. et al. (Sep., 2002). “Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation,”Circulation106:1610-1613.
Durham, S.K. et al. (1999). “The Heparin Binding Domain of Insulin-Like Growth Factor Binding Protein (IGFBP)-3 Increases Susceptibility of IGFBP-3 to Proteolysis,”Horm. Metab. Res.31:216-225.
Eliceiri, B.P. and Cheresh, D.A. (2000). “Role of αν Integrins During Angiogenesis,”The Cancer Journal6(Supp. 3):S245-S249.
Favoni, R. E. et al. (1998). “Modulation of the Insulin-Like Growth Factor-I System by N-(4-Hydroxyphenyl)-Retinamide in Human Breast Cancer Cell Lines,”Br. J. Cancer77(12):2138-2147.
Felding-Habermann, B. et al. (2001). “Integrin Activation Controls Metastasis in Human Breast Cancer,”Proc. Natl. Acad. Sci. USA98(4):1853-1858.
Ferrucci, J.T. (1991). “Iron Oxide Enhanced MR Imaging of the Liver and Spleen: Review of the First Five Years,”Keio J. Med.40(4):206-214.
Ferry, R.J. et al. (1999). “Cellular Actions of Insulin-Like Growth Factor Binding Proteins,”Horm. Metab. Res.31:192-202.
Firth, S.M. et al. (1998). “Structural Determinants of Ligand and Cell Surface Binding of Insulin-Like Growth Factor-Binding Protein-3,”J. Biol. Chem.273(5):2631-2638.
Fowlkes, J.L. and Serra, D.M. (1996). “Characterization of Glycosaminoglycan-Binding Domains Present in Insulin-Like Growth Factor-Binding Protein-3,”J. Biol. Chem.271(25):14676-14679.
Fowlkes, J.L. et al. (1995). “Insulin-Like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3) Functions as an IGF-Reversible Inhibitor of IGFBP-4 Proteolysis,”J. Biol. Chem.270(46):27481-27488.
Fowlkes, J.L. et al. (1997). “Heparin-Binding, Highly Basic Regions Within the Thyroglobulin Type-1 Repeat of Insulin-Like Growth Factor (IGF)-Binding Proteins (IGFBPs)-3, -5, and -6 Inhibit IGFBP-4 Degradation,”Endocrinology138(6):2280-2285.
Futterman, L.G. and Lemberg, L. (Sep., 2002). “High-Sensitivity C-Reactive Protein Is the Most Effective Prognostic Measurement of Acute Coronary Events,”American Journal of Critical Care11(5):482-486.
Genbank accession No. BC031217, Jun. 13, 2002, located at <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21411477&dopt=GenBank> visited on Feb. 14, 2003. (Two pages.)
Ghosh, P. et al. (1995). “The Structure of an Intermediate in Class II MHC Maturation: CLIP Bound to HLA-DR3,”Nature378:457-462.
Gill, Z.P. et al. (1997). “Insulin-Like Growth Factor-Binding Protein (IGFBP-3) Predisposes Breast Cancer Cells to Programmed Cell Death in a Non-IGF-Dependent Manner,”J. Biol. Chem.272(41):25602-25607.
Giuliano, M. et al. (1998). “Induction of Apoptosis in Human Retinoblastoma Cells by Topoisomerase Inhibitors,”Invest. Ophthalmol. Vis. Sci.39(8):1300-1311.
Green, D.A. et al. (2001).
Audet Maury
Bioexpertise LLC
Morrison & Foerster / LLP
Tate Christopher R.
LandOfFree
IGF-binding protein-derived peptide or small molecule does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IGF-binding protein-derived peptide or small molecule, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF-binding protein-derived peptide or small molecule will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3434104